All Outputs (14)
Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors (2025)
Journal Article
Over the past few years, immune checkpoint inhibitors resulted in magnificent and durable successes in treating cancer; however, only a minority of patients respond favorably to the treatment due to a broad-spectrum of tumor-intrinsic and tumor-extri... Read More about Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors.
Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targets. (2025)
Journal Article
Hepatocellular carcinoma (HCC) is one of the common malignant cancers worldwide. Although immunotherapy has improved the treatment outcome in HCC, a significant percentage of patients with advanced HCC still cannot benefit from immunotherapy. Therefo... Read More about Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targets..
The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy. (2025)
Journal Article
Colorectal cancer (CRC) is a common cancer with high mortality rates. Despite progress in treatment, it remains an incurable disease for many patients. In CRC, the tumor microenvironment (TME) plays critical roles in tumor growth, progression, patien... Read More about The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy..
Effect of boswellic acids on the expression of PD-1 and TIGIT immune checkpoints on activated human T cells. (2025)
Journal Article
Boswellic acids (BAs) have been documented as anti-inflammatory agents with the potential to regulate immune responses. However, their impacts on the expression level of immune checkpoint (IC) molecules in T cells have never been reported. By using f... Read More about Effect of boswellic acids on the expression of PD-1 and TIGIT immune checkpoints on activated human T cells..
Resistance mechanisms to immune checkpoint inhibitors: updated insights (2025)
Journal Article
The last decade has witnessed unprecedented succusses with the use of immune checkpoint inhibitors in treating cancer. Nevertheless, the proportion of patients who respond favorably to the treatment remained rather modest, partially due to treatment... Read More about Resistance mechanisms to immune checkpoint inhibitors: updated insights.
Effects of 1H-1,2,3-Triazole Derivatives of 3-O-Acetyl-11-Keto-Beta-Boswellic Acid from Boswellia sacra Resin on T-Cell Proliferation and Activation (2024)
Journal Article
Meyiah, A., Avula, S. K., Al-Harrasi, A., & Elkord, E. (in press). Effects of 1H-1,2,3-Triazole Derivatives of 3-O-Acetyl-11-Keto-Beta-Boswellic Acid from Boswellia sacra Resin on T-Cell Proliferation and Activation. Pharmaceuticals, 17(12), 1650. https://doi.org/10.3390/ph17121650Background: 3-O-acetyl-11-keto-β-boswellic acid (β-AKBA), a triterpene natural product, is one of the main natural products of Boswellia sacra resin (BSR) and has reported biological and immunomodulatory effects. 1H-1,2,3-triazole derivatives of β-AK... Read More about Effects of 1H-1,2,3-Triazole Derivatives of 3-O-Acetyl-11-Keto-Beta-Boswellic Acid from Boswellia sacra Resin on T-Cell Proliferation and Activation.
Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials (2024)
Journal Article
Ren, K., Hamdy, H., Meyiah, A., & Elkord, E. (in press). Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials. Frontiers in Immunology, 15, 1501613. https://doi.org/10.3389/fimmu.2024.1501613Lymphocyte-activation gene 3 (LAG-3) has emerged as a key immune checkpoint regulating immune responses in the context of cancer. The inhibitory effect of LAG-3-expressing T cells contributes to suppressing anti-tumor immunity and promoting tumor pro... Read More about Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials.
Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach? (2024)
Journal Article
Tripp, R. A., Cui, H., & Elkord, E. (2024). Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?. Vaccines, 12(12), 1306. https://doi.org/10.3390/vaccines12121306The discovery of immune checkpoints (ICs) has pushed cancer treatment into the next era. As an emerging immune checkpoint, the TIGIT/CD155 axis inhibits the cytotoxicity of T and NK cells through multiple pathways. Immune checkpoint inhibitors (ICIs)... Read More about Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?.
Editorial: Novel biomarkers in tumor immunity and immunotherapy (2024)
Journal Article
Matsutani, T., Akbay, E., & Elkord, E. (in press). Editorial: Novel biomarkers in tumor immunity and immunotherapy. Frontiers in Immunology, 15, 1405082. https://doi.org/10.3389/fimmu.2024.1405082
What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes? (2024)
Journal Article
Meyiah, A., & Elkord, E. (in press). What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes?. Expert Review of Clinical Immunology, 1-7. https://doi.org/10.1080/1744666X.2024.2334258Forkhead box P3 (FoxP3) transcription factor plays critical roles in controlling immune responses and cancer progression in different cancers. FoxP3 expression within the tumor microenvironment (TME) may influence clinical outcomes negatively or posi... Read More about What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes?.
The integrative multi-omics approach identifies the novel competing endogenous RNA (ceRNA) network in colorectal cancer (2023)
Journal Article
Circular RNAs (circRNA) are known to function as competing endogenous RNA (ceRNA) in various cancers by regulating microRNAs (miRNA). However, in colorectal cancer (CRC), the precise pathological role of circ000240/miRNA/mRNA remains indeterminate. T... Read More about The integrative multi-omics approach identifies the novel competing endogenous RNA (ceRNA) network in colorectal cancer.
Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein (2023)
Journal Article
Waqas, M., Halim, S. A., Alsalman, A., Khan, A., Elkord, E., & Al-Harrasi, A. (2023). Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein. Journal of Biomolecular Structure and Dynamics, 41(24), 14771-14785. https://doi.org/10.1080/07391102.2023.2188958Human immune system is specialized in distinguishing normal cells from foreign particles mainly through proteins expressed on immune cells called ‘checkpoints’. Immune checkpoints work as a switch to activate and deactivate immune responses. T cells... Read More about Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein.
Correlations between Circulating and Tumor-Infiltrating CD4+ T Cell Subsets with Immune Checkpoints in Colorectal Cancer (2022)
Journal Article
Al-Mterin, M. A., Murshed, K., & Elkord, E. (2022). Correlations between Circulating and Tumor-Infiltrating CD4+ T Cell Subsets with Immune Checkpoints in Colorectal Cancer. Vaccines, 10(4), 538. https://doi.org/10.3390/vaccines10040538T regulatory cells (Tregs) play different roles in the regulation of anti-tumor immunity in colorectal cancer (CRC), depending on the presence of different Treg subsets. We investigated correlations between different CD4+ Treg/T cell subsets in CRC p... Read More about Correlations between Circulating and Tumor-Infiltrating CD4+ T Cell Subsets with Immune Checkpoints in Colorectal Cancer.